Your browser doesn't support javascript.
loading
Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques.
Theel, Willy; Boxma-de Klerk, Bianca M; Dirksmeier-Harinck, Femme; van Rossum, Elisabeth F C; Kanhai, Danny A; Apers, Jan; van Dalen, Bas M; de Knegt, Robert J; Holleboom, Adriaan G; Tushuizen, Maarten E; Grobbee, Diederick E; Wiebolt, Janneke; Castro Cabezas, Manuel.
Afiliación
  • Theel W; Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
  • Boxma-de Klerk BM; Obesity Center CGG, Rotterdam, The Netherlands.
  • Dirksmeier-Harinck F; Department of Statistics and Education, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
  • van Rossum EFC; Department of Gastroenterology and Hepatology, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
  • Kanhai DA; Obesity Center CGG, Rotterdam, The Netherlands.
  • Apers J; Department of Internal Medicine, Division of Endocrinology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • van Dalen BM; Department of Pediatrics, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
  • de Knegt RJ; Department of Bariatric Surgery, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
  • Holleboom AG; Department of Cardiology, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
  • Tushuizen ME; Department of Gastroenterology and Hepatology, Erasmus Medical Centre, Rotterdam, The Netherlands.
  • Grobbee DE; Department of Vascular Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
  • Wiebolt J; Department of Gastroenterology and Hepatology, Leiden UMC, Leiden, The Netherlands.
  • Castro Cabezas M; Julius Centre for Health Science and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Obes Rev ; 23(8): e13481, 2022 08.
Article en En | MEDLINE | ID: mdl-35692179
The prevalence of nonalcoholic fatty liver disease (NAFLD) and the more severe and inflammatory type, nonalcoholic steatohepatitis (NASH), is increasing rapidly. Especially in high-risk patients, that is those with obesity, metabolic syndrome, and type 2 diabetes mellitus, the prevalence of NAFLD can be as high as 80% while NASH may be present in 20% of these subjects. With the worldwide increase of obesity, it is most likely that these numbers will rise. Since advanced stages of NAFLD and NASH are strongly associated with morbidity and mortality-in particular, cardiovascular disease, liver cirrhosis, and hepatocellular carcinoma-it is of great importance to identify subjects at risk. A great variety of noninvasive tests has been published to diagnose NAFLD and NASH, especially using blood- and imaging-based tests. Liver biopsy remains the gold standard for NAFLD/NASH. This review aims to summarize the different mechanisms leading to NASH and liver fibrosis, the different noninvasive liver tests to diagnose and evaluate patients with severe obesity.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Obesidad Mórbida / Diabetes Mellitus Tipo 2 / Enfermedad del Hígado Graso no Alcohólico Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Obes Rev Asunto de la revista: METABOLISMO Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Obesidad Mórbida / Diabetes Mellitus Tipo 2 / Enfermedad del Hígado Graso no Alcohólico Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Obes Rev Asunto de la revista: METABOLISMO Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido